You are here » News

News

Entries for 2008

July 16, 2008

Lausanne, Switzerland – July 16, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan’s Ministry of Health, Labor and Welfare has approved Differin® Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan. The drug will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi.

Read more...

Posted in: Press release

April 11, 2008

Lausanne, Switzerland – April 11, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its acquisition of CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI).   As a result of the transaction, CollaGenex has become a wholly owned subsidiary of Galderma Laboratories.

Read more...

Posted in: Press release

April 07, 2008

Lausanne, Switzerland – April 7, 2008 – Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its all cash tender offer for CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI).  The tender offer expired at 12:00 Midnight, New York City time, at the end of Friday, April 4, 2008.

Read more...

Posted in: Press release

March 07, 2008

Lausanne Switzerland, 7 March, 2008 – Galderma Pharma, S.A. announces an agreement with ZARS Pharma, Inc. giving Galderma exclusive rights for all markets outside the USA and Canada for promotion and distribution of a novel topical anesthetic cream. This partnership follows an agreement signed last year between Galderma and ZARS Pharma for the promotion and distribution of Pliaglis™ in the USA and Canada.

Read more...

Posted in: Press release

February 26, 2008

Lausanne, Switzerland and Newtown, PA – February 26, 2008 Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI) today announced a definitive agreement pursuant to which Galderma’s U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex. The transaction was unanimously approved by the boards of directors of Galderma and CollaGenex.

Read more...

Posted in: Press release

 1 / 1  

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos